FrangoulH, AltshulerD, CappelliniMD, et al.CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New Engl J Med, 2021; 384:252–260.
2.
LocatelliF, Ailinca-LuchianS, BobruffY, et al. CTX001 for transfusion-dependent B-thalassemia: Safety and efficacy results from the ongoing CLIMB THAL-111 study of autologous CRISPR-Cas9-modified CD34+ hematopoietic stem and progenitor cells. Abstract No. EP733. June 10, 2021. Joint European Hematology Association-American Society of Hematology (EHA-ASH) Symposium. https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/325492/franco.locatelli.ctx001.for.transfusion-dependent.-thalassemia.safety.and.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dctx001 (last accessed June14, 2021 via European Hematology Association Virtual Congress website). Google Scholar.
3.
GruppS, BlobergerN, CampbellC, et al. CTX001 for sickle cell disease: Safety and efficacy results from the ongoing CLIMB SCD-121 study of autologous CRISPR-Cas9-modified CD34+ hematopoietic stem and progenitor cells. Abstract No. EP736. June 10, 2021. Joint European Hematology Association-American Society of Hematology (EHA-ASH) Symposium. https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/325494/stephan.grupp.ctx001.for.sickle.cell.disease.safety.and.efficacy.results.from.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dctx001 (last accessed June14, 2021 via European Hematology Association Virtual Congress website). Google Scholar.
4.
Vertex and CR, ISPRTherapeutics. Vertex and CRISPR therapeutics present new data in 22 patients with greater than 3 months follow-up post-treatment with investigational CRISPR/Cas9 gene-editing therapy, CTX001™ at European Hematology Association Annual Meeting. June 11, 2021. https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-present-new-data-22-patients (last accessed June12, 2021). Google Scholar.
5.
Bluebird Bio. Bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies. June 7, 2021. https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-lifting-fda-clinical-hold-sickle-cell (last accessed June12, 2021). Google Scholar.
6.
Charles River Laboratories. Charles river laboratories to acquire vigene biosciences to enhance gene therapy capabilities. May 16, 2021. https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-acquire-vigene-biosciences-enhance (last accessed June12, 2021). Google Scholar.
7.
Biogen and Ginkgo Bioworks. Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform. May 21, 2021. https://investors.biogen.com/news-releases/news-release-details/biogen-and-ginkgo-bioworks-announce-collaboration-and-license (last accessed June12, 2021). Google Scholar.
8.
Codexis and Takeda Pharmaceutical. Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder. June 10, 2021. https://ir.codexis.com/news-events/press-releases/detail/293/codexis-and-takeda-expand-strategic-collaboration-and (last accessed June12, 2021). Google Scholar.
9.
Alcyone Therapeutics. Alcyone therapeutics launches to advance next-generation gene therapies for CNS disorders. June 9, 2021. https://www.prnewswire.com/news-releases/alcyone-therapeutics-launches-to-advance-next-generation-gene-therapies-for-cns-disorders-301308534.html (last accessed June12, 2021). Google Scholar.
